Search Results

A Randomized Trial of Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age -STUDY00005027

To determine if dichoptic therapy using Luminopia is confirmed to be non- inferior to stardard part-time patching for best- corrected visual...

A prospective observational study to describe clinical outcomes of alglucosidase alfa treatment in patients ≤6 months of age with infantile-onset Pompe disease (IOPD)-STUDY00003887

An observational study that follows IOPD patients who start Lumizyme, a standard of care treatment for Pompe disease, at under 6 months of age.

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine: REBUILD-1 Study-STUDY00002625

This study is being done to see how safe galcanezumab is and how well it will work to help reduce the number of episodic migraines in children and...

AALL2131 An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leu-STUDY00005534

AALL2131 is a multi-center, international clinical trial designed to improve outcomes and reduce treatment-related toxicity in pediatric patients...

AALL1821: Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC # 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years Old with First Relapse-STUDY00003220

This is a phase 2 study for 1st relapse B-ALL. The large goal is to try to induce remission in the highest risk group of patients with...

A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN)-STUDY00002933

This two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator...

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine: REBUILD-2 Study-STUDY00002627

This study is being done to see how safe galcanezumab is and how well it will work to help adolescents with chronic migraines.

A Post-Authorization Safety Study (PASS) to Assess Long-term Safety in Patients with Pompe Disease Treated with Avalglucosidase alfa in the Real-World Setting: the SAVANT (Safety assessment of AValglucosidase Alfa as a Novel Treatment) study-STUDY00005276

To collect long term safety data and evaluate the important identified risk of infusion associated reactions (IARs) including hypersensitivity and...

Checklist for New Tracheostomy and Ventilator Discharges: When Your Child is Ready to Go Home from the Hospital

Checklist for New Tracheostomy and Ventilator Discharges: When Your Child is Ready to Go Home from the Hospital Print this page Download No main body...

Unlocking the Mystery of COVID-19 in Children

Seattle Children’s Research Institute is the largest pediatric infectious disease research organization in the nation. More than 50 research studies...